In general, the frequency of developing malignancies other than breast and ovarian cancers differs between BRCA1 and BRCA2 mutations. BRCA1 carriers predominantly suffer from breast and ovarian cancers and the development of cancers for other sites is less frequent than for BRCA2 mutation carriers. This evidence concerns the gene BRCA1 and ovarian carcinoma.